Carcinoma of Unknown Primary (CUP) — a clinically and biologically heterogeneous group of metastatic malignancies defined by the absence of an identifiable primary tumor site after standardized diagnostic workup, accounting for approximately 3–5% of all cancer diagnoses worldwide and representing approximately 30,000–45,000 new cases annually in the United States, ranking as the fourth most common cause of cancer mortality in some registry analyses — presents clinically with symptoms referable to the dominant metastatic site: cervical lymphadenopathy (25–30% of CUP), axillary lymphadenopathy, inguinal lymphadenopathy, liver metastases causing abdominal pain and elevated liver enzymes, pleural or peritoneal carcinomatosis causing dyspnea or ascites, bone metastases causing pain or pathologic fracture, and brain metastases causing neurologic symptoms; CUP is by definition diagnosed after standard CT chest-abdomen-pelvis, FDG-PET/CT, serum tumor markers (CEA, CA125, CA19-9, AFP, PSA, β-hCG, LDH), and clinically directed endoscopy (upper endoscopy, colonoscopy) fail to identify the primary tumor. Pathologically, CUP is classified by histology — adenocarcinoma (60%), squamous cell carcinoma (5%), poorly differentiated carcinoma (29%), and undifferentiated carcinoma (5%) — with immunohistochemistry essential for subtype characterization: CK7/CK20 pattern for site of origin likelihood (CK7+/CK20- favors upper GI, lung, breast, ovary; CK7-/CK20+ favors colorectal, Merkel cell), TTF-1 (lung adenocarcinoma), CDX2 (colorectal), ER/PR/GCDFP (breast), PSA/NKX3.1 (prostate), AFP/arginase (hepatocellular), chromogranin/synaptophysin (neuroendocrine), p63/p40/CK5/6 (squamous), PAX8 (ovarian, renal), GATA3 (breast, urothelial), WT1 (ovarian), SOX10 (melanoma), and S100 (melanoma, neural). Clinically defined favorable subsets have been recognized as CUP variants requiring specific treatment: poorly differentiated carcinoma with midline distribution (extragonadal germ cell tumor-like, treat with BEP), squamous cell carcinoma involving cervical lymph nodes (treat as head and neck squamous cell carcinoma), adenocarcinoma in a woman with peritoneal carcinomatosis (treat as primary peritoneal/ovarian cancer with carboplatin-paclitaxel), isolated axillary lymphadenopathy in women (treat as occult primary breast cancer), single site of metastasis amenable to resection (treat with curative intent), and neuroendocrine carcinoma (treat as primary neuroendocrine tumor with cisplatin-etoposide or octreotide-based therapy for well-differentiated).
The transformative advance in contemporary CUP management is comprehensive genomic profiling (CGP) by next-generation sequencing — tumor tissue RNA and DNA sequencing by Foundation Medicine FoundationOne CDx, Tempus xT, Caris Molecular Intelligence, or Guardant360 liquid biopsy — which identifies clinically actionable somatic mutations in 30–40% of CUP patients, determines tissue-of-origin probability from transcriptomic profiles (CancerSEEK, Caris TOO, Tempus TO) with accuracy of 80–90% for top-2 predictions, and guides molecularly directed therapy — EGFR-mutated CUP (treat as lung adenocarcinoma with osimertinib), BRCA1/2-mutated CUP with homologous recombination deficiency (olaparib, niraparib), MSI-H/MMR-deficient CUP (pembrolizumab), BRAF V600E (dabrafenib-trametinib), HER2-amplified (trastuzumab combinations), RET fusion (selpercatinib), NTRK fusion (larotrectinib), FGFR2/3 alteration (erdafitinib), TMB-high (pembrolizumab), and CDK4/6-amplified ER+ molecular signature (palbociclib-letrozole). For the 60–70% of CUP without actionable mutations, empirical platinum-based chemotherapy (carboplatin-paclitaxel, GEMOX, BEP depending on histology and subset) remains the standard of care, achieving objective response rates of 25–40% but with median overall survival of 9–12 months for unfavorable CUP.
CUP technology platforms — whether supporting multi-specialty CUP tumor boards coordinating primary search workup (CT chest-abdomen-pelvis, FDG-PET/CT, mammogram, colonoscopy, EGD, PSA, β-hCG, AFP, CA125, CA19-9 in sex-appropriate standardized primary search panels), NGS report routing platforms delivering Foundation Medicine or Tempus comprehensive genomic profiling results with tissue-of-origin probability and actionable alteration summaries to multidisciplinary tumor board review, IHC panel aggregation platforms consolidating the multi-site immunohistochemical staining results from the pathologist's primary site-of-origin panel into a unified diagnostic summary, molecularly directed therapy prescribing platforms managing pembrolizumab, osimertinib, olaparib, dabrafenib-trametinib, larotrectinib, and selpercatinib administration and toxicity monitoring, empirical carboplatin-paclitaxel infusion platforms for unfavorable CUP, and treatment response tracking platforms integrating CT RECIST assessments, tumor marker trending, and clinical status for the multi-specialty CUP tumor board — must maintain the availability and performance standards that CUP's diagnostic workup complexity, NGS turnaround time criticality, multi-specialty tumor board coordination requirements, and molecularly directed therapy management demands. This guide explains why CUP tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy that matches the primary search coordination, NGS profiling, IHC aggregation, multi-specialty tumor board, and molecularly directed therapy complexity of modern CUP management.
Why CUP Tech Platforms Require Specialized Monitoring Attention
CUP management is defined by the diagnostic urgency of primary search workup completion — where a patient presenting with malignant adenopathy or liver metastases and an unidentified primary must complete CT chest-abdomen-pelvis, FDG-PET/CT, sex-appropriate endoscopy, tumor markers, and IHC panel review within 2–4 weeks before performance status deterioration forecloses treatment options — the NGS profiling turnaround criticality where comprehensive genomic profiling results from Foundation Medicine or Tempus must reach the tumor board within 2–3 weeks of tissue submission to inform molecularly directed therapy initiation before empirical chemotherapy depletes the patient's treatment course, the multi-specialty tumor board coordination requirements where medical oncology, radiation oncology, surgical oncology, pathology, and radiology must simultaneously review NGS results, IHC panels, and imaging across a multidisciplinary platform, the IHC panel aggregation complexity where 15–25 immunostains performed in multiple tissue sections across multiple laboratory sessions must be consolidated into a primary site probability assessment, and the molecularly directed therapy monitoring demands where MSI-H patients on pembrolizumab, BRCA-mutated patients on PARP inhibitors, and BRAF-mutated patients on dabrafenib-trametinib require toxicity monitoring protocols from their respective tissue-of-origin targeted therapy frameworks applied to a CUP patient context. Technology failures in these domains create disruptions calibrated to the diagnostic urgency, NGS timing, and multi-specialty coordination requirements of CUP.
NGS report routing platforms determine molecularly directed therapy access with narrow windows. Foundation Medicine FoundationOne CDx or Tempus xT comprehensive genomic profiling — where a 2–3 week turnaround from tissue submission to NGS report delivery must align with the tumor board review schedule, where actionable alterations (MSI-H, BRAF V600E, BRCA2, EGFR exon 19 del, NTRK3 fusion) identified in the NGS report must be routed to the treating oncologist for FDA-approved or NCCN-recommended molecularly directed therapy initiation, and where the CancerSEEK or Caris Molecular Intelligence tissue-of-origin probability (e.g., 72% colorectal, 61% pancreatic-biliary) guides site-specific empirical therapy selection for the 60–70% of CUP without high-confidence actionable alterations — depends entirely on platforms capable of receiving the NGS PDF report, extracting structured alteration data, and routing it to the tumor board review platform and treating oncologist within hours of report delivery. Monitor NGS routing platforms at 1-minute intervals during business hours.
Multi-specialty tumor board platforms coordinate the diagnostic synthesis for every CUP patient. CUP tumor board review — where a medical oncologist, pathologist (reviewing IHC panel results and tissue adequacy for NGS), radiologist (reviewing CT and PET/CT for dominant metastatic site and occult primary candidate lesions), radiation oncologist (evaluating oligometastatic disease amenable to stereotactic body radiotherapy), surgical oncologist (evaluating the rare resectable single-site CUP), and genetic counselor (for BRCA1/2 germline testing in CUP with BRCA somatic alteration) must simultaneously access the NGS report, IHC panel summary, CT and PET/CT imaging, serum tumor marker trends, and prior tissue biopsy pathology reports in a single platform session — depends on integrated platforms that aggregate these data sources, schedule the tumor board agenda, and capture tumor board consensus treatment recommendations for the oncologist's clinical note. Monitor tumor board platforms at 1-minute intervals during board hours.
IHC panel aggregation platforms consolidate the primary site workup. A standard CUP IHC panel — CK7, CK20, TTF-1, CDX2, ER, PR, GCDFP, PSA, NKX3.1, chromogranin, synaptophysin, PAX8, GATA3, p63, p40, AFP, arginase, SOX10, S100, WT1, and site-directed additional stains — performed across multiple laboratory runs on serial tissue sections must be consolidated into a structured primary site probability assessment that integrates staining patterns with the CK7/CK20 matrix and clinical context. Platforms that aggregate multi-session IHC results, display the staining pattern matrix, and generate the pathologist's primary site differential summary must remain available throughout the 1–2 week IHC workup period and at the time of tumor board presentation. Monitor IHC platforms at 1-minute intervals during pathology laboratory hours.
Imaging-directed primary search platforms must deliver actionable PET/CT and MRI results. FDG-PET/CT for CUP primary search — where uptake in a gastric wall, colonic mucosa, pancreatic head, thyroid nodule, or endometrial lesion provides the actionable primary site candidate that directs targeted biopsy or endoscopy — and MRI brain, pelvis, and breast for sex-appropriate primary search must be scheduled within the diagnostic workup window, with radiologist structured report routing to the treating oncologist for expedited primary site biopsy scheduling. Monitor imaging platforms at 1-minute intervals during business hours.
What to Monitor on a CUP Tech Platform
Primary Search Imaging and Tumor Marker Workup
Monitor CT chest-abdomen-pelvis with contrast scheduling and radiologist structured report routing for dominant metastatic site characterization and occult primary candidate identification, FDG-PET/CT for whole-body metabolic primary search with SUVmax documentation for primary candidate lesions, mammogram and breast MRI for women with CUP and axillary adenopathy or peritoneal carcinomatosis, MRI brain for neurologic symptoms or when treatment with CNS-penetrant agents is considered, colonoscopy and EGD scheduling coordination for GI primary search with pathology routing, serum tumor marker panel scheduling (CEA, CA19-9, CA125, AFP, β-hCG, PSA for males, LDH, inhibin B for germ cell suspicion) with results integration into the primary search summary, and testicular ultrasound for men with mediastinal or retroperitoneal adenopathy at 1-minute intervals during business hours. Alert immediately — primary search imaging platform failures delay the CT and PET/CT results that define the dominant metastatic site distribution and primary candidate lesions in a CUP patient whose treatment selection depends on this diagnostic synthesis, and a 1–2 week platform outage in a patient with rapidly progressive liver metastases can eliminate the performance status window for NGS-directed therapy.
Comprehensive Genomic Profiling and NGS Report Routing
Monitor Foundation Medicine FoundationOne CDx, Tempus xT, Caris Molecular Intelligence, or GRAIL Galleri tissue submission records with adequacy documentation (minimum tumor fraction, minimum tumor nuclei count for NGS success), specimen shipment chain-of-custody tracking, turnaround time monitoring from specimen receipt to report delivery (target 10–14 business days), NGS report PDF receipt and structured alteration data extraction, actionable alteration flagging (MSI-H, TMB-high, BRCA1/2, EGFR mutation, ALK/ROS1 fusion, NTRK fusion, BRAF V600E, HER2 amplification, RET fusion, FGFR alteration), tissue-of-origin probability score routing (CancerSEEK signal, Caris TOO, Tempus TO with confidence level), oncologist notification of NGS results, and liquid biopsy (Guardant360, Foundation Liquid CDx) scheduling for tissue-insufficient or rapidly deteriorating patients at 1-minute intervals during business hours. Alert immediately — NGS result routing platform failures that prevent Foundation Medicine or Tempus report delivery from reaching the oncologist within hours of availability delay tumor board review by one full weekly cycle (7 days), eliminating the molecularly directed therapy initiation window for a CUP patient whose performance status window for targeted therapy may close within 2–3 weeks of NGS report availability.
IHC Panel Aggregation and Pathology Reporting
Monitor immunohistochemical staining run scheduling (CK7, CK20, TTF-1, CDX2, ER, PR, PSA, NKX3.1, chromogranin, synaptophysin, PAX8, GATA3, p63, p40, AFP, arginase, SOX10, S100, WT1, GCDFP), multi-session IHC result consolidation into the CK7/CK20 primary site matrix documentation, pathologist primary site differential probability report generation with clinicopathologic correlation, tissue adequacy re-biopsy documentation when initial IHC tissue is insufficient, site-directed additional IHC ordering (e.g., p16 for HPV-associated squamous cell carcinoma in cervical adenopathy CUP, calretinin/WT1 for peritoneal carcinomatosis), tumor board IHC presentation summary generation, and pathology laboratory QC records for IHC controls at 1-minute intervals during pathology laboratory business hours. Alert immediately — IHC aggregation platform failures that delay the pathologist's primary site differential summary prevent the tumor board from completing the diagnostic synthesis required to select between site-specific (treat-as-primary) and empirical CUP therapy, forcing empirical carboplatin-paclitaxel in a patient who might have received larotrectinib for an NTRK fusion or site-specific first-line therapy if the IHC and NGS results had been synthesized on schedule.
Multi-Specialty CUP Tumor Board Coordination
Monitor tumor board agenda management with weekly or biweekly scheduling documentation, pre-board case preparation with NGS report, IHC panel summary, CT and PET/CT imaging, and serum tumor marker integration into the tumor board presentation template, real-time imaging display during board review (CT, PET/CT, MRI), board consensus treatment recommendation documentation with oncologist, pathologist, radiologist, radiation oncologist, surgical oncologist, and genetic counselor attestation, post-board clinical note generation with treatment plan documentation, clinical trial eligibility screening documentation (particularly Phase 2 molecular basket trials for actionable CUP alterations), and tumor board audit trail for complex diagnostic and treatment decisions at 1-minute intervals during board hours. Alert immediately — CUP tumor board platform failures during the weekly board session — where 8–12 newly diagnosed CUP patients are reviewed with simultaneous access to NGS reports, IHC panels, CT/PET imaging, and prior biopsy pathology — eliminate the multi-specialty consensus platform that drives every treatment decision in a malignancy where no single specialist has the information to complete the diagnosis without the board synthesis.
Molecularly Directed Therapy Prescribing and Toxicity Monitoring
Monitor pembrolizumab (200 mg IV every 3 weeks) prescribing, pharmacy preparation, and immune-related adverse event (irAE) surveillance for MSI-H/MMR-deficient CUP (pneumonitis, colitis, hepatitis, thyroiditis, adrenal insufficiency); osimertinib (80 mg/day orally) dose management, QTc monitoring, and interstitial lung disease surveillance for EGFR-mutated CUP treated as lung adenocarcinoma; olaparib (300 mg BID) or niraparib (200–300 mg/day) PARP inhibitor prescribing and CBC myelosuppression monitoring for BRCA1/2-mutated CUP; dabrafenib (150 mg BID) and trametinib (2 mg/day) dose management and fever, rash, and cardiac function monitoring for BRAF V600E-mutated CUP; larotrectinib (100 mg BID) or entrectinib (600 mg/day) dose management and neurologic adverse event documentation for NTRK fusion-positive CUP; selpercatinib (160 mg BID) QTc monitoring and hepatotoxicity surveillance for RET fusion-positive CUP; and tumor response assessment by RECIST CT every 2–3 cycles across all molecularly directed agents at 1-minute intervals during clinical hours. Alert immediately — molecularly directed therapy toxicity platform failures for CUP patients receiving PARP inhibitors (where CBC-confirmed myelosuppression requires dose hold), pembrolizumab (where Grade 3 irAE requires high-dose corticosteroids), or BRAF inhibitors (where fever and cardiovascular events require dose interruption) eliminate the toxicity monitoring platform during events that are both common and immediately actionable.
Empirical Carboplatin-Paclitaxel and GEMOX Administration
Monitor carboplatin AUC5 (or AUC6) and paclitaxel 175 mg/m² (or 200 mg/m²) every 21 days pre-cycle CBC (ANC ≥1.5 × 10⁹/L, platelets ≥100 × 10⁹/L) and creatinine clearance for carboplatin AUC calculation, paclitaxel hypersensitivity premedication records (dexamethasone, diphenhydramine, ranitidine), gemcitabine-oxaliplatin (GEMOX: gemcitabine 1000 mg/m² day 1 and 8, oxaliplatin 100 mg/m² day 1) pre-cycle eligibility for GI-primary molecular subtype CUP, BEP (bleomycin-etoposide-cisplatin) scheduling for extragonadal germ cell tumor-like poorly differentiated CUP, response assessment CT at cycles 2 and 4, second-line therapy transition documentation for progressive disease, and palliative care integration records for unfavorable CUP patients with rapid progression at 1-minute intervals during infusion days. Alert immediately — empirical chemotherapy platform failures on treatment days for unfavorable CUP patients receiving carboplatin-paclitaxel disrupt the eligibility verification and dose administration workflow for patients whose median OS of 9–12 months means that treatment delays represent a meaningful fraction of the expected treatment benefit period.
Clinical Trial Eligibility and Molecular Basket Trial Enrollment
Monitor ClinicalTrials.gov-linked molecular eligibility screening documentation for NCI-MATCH, MyPathway, TAPUR, and tumor-agnostic basket trial enrollment, molecular alteration-to-trial matching records for BRAF V600E (TAPUR), ERBB2 amplification (MyPathway), BRCA (olaparib combinations), KRAS G12C (sotorasib), and RET/NTRK/FGFR trials, IRB protocol version verification for enrolled CUP patients, protocol-specified biomarker collection and shipment records (ctDNA, archival tissue, serial biopsies), trial eligibility confirmation documentation (prior therapy lines, organ function criteria, washout periods), and patient-reported outcome instrument collection scheduling at 1-minute intervals during business hours for enrolled patients. Alert immediately — clinical trial enrollment platform failures for a CUP patient enrolled in a molecular basket trial delay protocol-required biomarker collection and eligibility re-verification that can trigger protocol deviation review and potential trial removal — eliminating access to an investigational agent that may represent the patient's only molecularly matched treatment opportunity.
Treatment Response Tracking and Multi-Specialty Follow-up
Monitor RECIST 1.1 CT chest-abdomen-pelvis response assessment at cycles 2, 4, and every 3 cycles thereafter with target lesion sum of diameters trending, serum tumor marker trending (CEA, CA19-9, CA125, AFP as applicable) correlated with imaging response, patient-reported outcome documentation (ECOG PS, symptom burden, pain scores) at each visit, radiation oncology follow-up for stereotactic body radiotherapy (SBRT)-treated oligometastatic CUP, surgical oncology follow-up for resected single-site CUP, palliative care integration documentation for symptom management, and hospice transition documentation for patients with rapidly progressive unfavorable CUP at 2-minute intervals during business hours. Alert on sustained failures — treatment response tracking platform failures prevent the oncologist from detecting rising tumor marker trends or worsening imaging that signals progressive disease and triggers second-line therapy or clinical trial enrollment discussions.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. CUP programs coordinate across medical oncology, pathology (IHC panel aggregation, NGS tissue processing), radiology (CT, PET/CT, MRI primary search), gastroenterology (colonoscopy, EGD for GI primary search), gynecologic oncology (peritoneal carcinomatosis CUP treated as ovarian), breast oncology (axillary CUP treated as occult primary breast), head and neck oncology (cervical squamous CUP treated as HNSCC), radiation oncology (SBRT for oligometastatic CUP), surgical oncology (single-site resectable CUP), genetic counseling (BRCA germline testing), palliative care, and molecular profiling vendor liaisons (Foundation Medicine, Tempus, Caris) — authentication failures simultaneously block the entire multidisciplinary platform that CUP's multi-specialty diagnostic synthesis and treatment requires.
SSL Certificates
Monitor SSL certificate expiry across all patient portals, NGS vendor report delivery platforms, IHC laboratory systems, tumor board coordination platforms, imaging systems, molecularly directed therapy prescribing platforms, and clinical trial management systems. Certificate errors disrupt NGS result routing, IHC panel aggregation, tumor board imaging access, and molecularly directed therapy prescribing workflows of CUP management.
HIPAA and Oncology Data Privacy Considerations
CUP technology platforms handle sensitive PHI including comprehensive genomic profiling results from Foundation Medicine or Tempus with actionable somatic mutation documentation and insurance discrimination implications, BRCA1/2 somatic alterations that may have germline implications requiring genetic counseling, tissue-of-origin probability scores that assign molecular diagnoses without histopathologic tissue-of-origin confirmation, immunohistochemical panel results, multiple site biopsy pathology documentation, multi-specialty tumor board consensus records, and treatment records across a diagnosis that carries profound prognostic uncertainty for patients and families. HIPAA Security Rule requirements for PHI availability and integrity apply across all platform components managing this PHI, with particular attention to the multi-vendor data flows involved in NGS report delivery from Foundation Medicine or Tempus to the oncology platform, where ePHI is transmitted between covered entity and business associate under Business Associate Agreements.
For platforms managing comprehensive genomic profiling reports with insurance-relevant alteration documentation — where a BRCA2 somatic mutation report routed to the oncology record may have germline implications that the patient has not yet been counseled about — privacy standards must ensure that NGS result routing follows the covered entity's controlled disclosure protocols before results reach non-treating parties. Availability monitoring provides operational documentation relevant to HIPAA Security Rule administrative safeguard compliance for oncology programs managing CUP's intersection of multi-specialty tumor board PHI, comprehensive genomic profiling results, molecularly directed therapy records, and clinical trial protocol documentation.
Alerting Strategy for CUP Tech Platforms
Immediate alerting during tumor board sessions: Multi-specialty CUP tumor board platforms — where simultaneous imaging display, NGS report review, IHC panel presentation, and treatment recommendation documentation cannot fail during a board session without eliminating the multi-specialty consensus platform for every CUP patient on the agenda.
Immediate business-hours alert: NGS report receipt and routing platforms, IHC panel aggregation platforms, primary search imaging result routing, molecular eligibility screening for clinical trial enrollment, and molecularly directed therapy toxicity monitoring platforms. Alert the moment these fail during active clinical encounters.
Immediate alerting during infusion sessions: Empirical carboplatin-paclitaxel, GEMOX, or BEP infusion administration platforms; molecularly directed therapy prescribing verification during initial cycle administration.
Sustained-failure alert (10–15 minutes): RECIST treatment response tracking, tumor marker trending platforms, palliative care integration documentation, and patient communication portals.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms CUP platform availability from the geographies where academic medical centers with multi-specialty CUP tumor boards, NGS-directed clinical trial programs, and comprehensive genomic profiling experience concentrate — important for patients traveling to high-volume centers where CUP's diagnostic complexity demands the multi-specialty expertise and molecular profiling infrastructure that regional oncology practices cannot maintain for such an uncommon diagnosis.
Status Page for CUP Care Team Communication
A real-time status page gives medical oncologists managing empirical carboplatin-paclitaxel or molecularly directed therapy cycles, pathologists aggregating IHC panel results for tumor board, radiologists reviewing PET/CT for primary site candidates, gastroenterologists scheduling colonoscopy for GI primary search, molecular pathology coordinators tracking Foundation Medicine turnaround time, genetic counselors assessing BRCA germline implications from NGS somatic reports, and trial coordinators verifying molecular eligibility for basket trial enrollment immediate platform visibility without requiring inbound IT support contact. During a tumor board platform outage on weekly board day where 10 newly diagnosed CUP patients are scheduled for multi-specialty review, a status page enables the tumor board chair to activate the contingency presentation protocol — pre-distributed case summaries and imaging links — without platform-dependent delay that would push CUP patients' treatment decisions into the following week.
Include the status page URL in tumor board platform downtime procedures, NGS report routing fallback procedures, IHC panel emergency access protocols, molecularly directed therapy prescribing contingency procedures, and clinical trial protocol deviation prevention procedures.
Vigilmon Setup for CUP Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Multi-specialty CUP tumor board platform (board days) | 1 min | Slack + PagerDuty (board hours) | | NGS report receipt and routing (Foundation Medicine / Tempus / Caris) | 1 min | Slack + PagerDuty (business hours) | | IHC panel aggregation / pathology laboratory | 1 min | Slack + PagerDuty (business hours) | | Primary search CT / PET-CT imaging result routing | 1 min | Slack + PagerDuty (business hours) | | Molecularly directed therapy toxicity monitoring (pembrolizumab, PARP inhibitor, BRAF inhibitor) | 1 min | Slack + PagerDuty (clinical hours) | | Clinical trial eligibility and molecular basket trial enrollment | 1 min | Slack + PagerDuty (business hours) | | Carboplatin-paclitaxel / GEMOX / BEP infusion administration | 1 min | Slack + PagerDuty (infusion hours) | | RECIST treatment response tracking | 2 min | Slack (business hours) | | Tumor marker trending (CEA, CA19-9, CA125, AFP) | 2 min | Slack (business hours) | | Patient communication portal | 2 min | Slack (business + evening hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure multi-specialty CUP tumor board platforms with immediate alerting during board sessions
- Add NGS report receipt and routing platforms with immediate business-hours alerting for Foundation Medicine, Tempus, and Caris report delivery
- Configure IHC panel aggregation and pathology laboratory platforms with immediate business-hours alerting
- Add primary search CT and PET/CT result routing platforms with immediate business-hours alerting
- Configure molecularly directed therapy toxicity monitoring platforms with immediate clinical-hours alerting
- Add clinical trial molecular eligibility and basket trial enrollment platforms with immediate business-hours alerting
- Configure empirical carboplatin-paclitaxel, GEMOX, or BEP infusion administration platforms with immediate infusion-hours alerting
- Add RECIST treatment response tracking with sustained-failure alerting
- Configure tumor marker trending with sustained-failure alerting
- Enable SSL certificate monitoring across all clinical, NGS vendor, pathology, tumor board, and clinical trial management domains
- Add the status page URL to tumor board downtime procedures, NGS report routing fallback procedures, IHC emergency access protocols, and molecularly directed therapy prescribing contingency procedures
Conclusion
CUP technology platforms are embedded in clinical decisions where NGS report routing platform availability on the day a Foundation Medicine FoundationOne CDx report becomes available — where a 62-year-old patient with CUP presenting as malignant liver metastases and a rising CEA of 120 U/mL has KRAS wild-type adenocarcinoma with a 78% colorectal tissue-of-origin probability, BRAF V600E mutation confirmed, and MSS microsatellite status on the 14-business-day NGS result, and the molecular oncology coordinator needs to route the dabrafenib-trametinib eligibility summary to the treating oncologist and the tumor board agenda for next Monday's session before the patient's Day 21 return visit — cannot fail when the 7-day delay from missed routing to the following week's tumor board eliminates the 3-week window before this patient's clinical deterioration forecloses targeted therapy eligibility; where multi-specialty tumor board platform availability on the weekly CUP board day — where the pathologist presenting the IHC summary (CK7+/CK20-, TTF-1 negative, CDX2 negative, ER weakly positive, GATA3 positive, PAX8 negative) for a woman with peritoneal carcinomatosis, the radiologist displaying the PET/CT confirming no identifiable primary site despite FDG-avid omental caking, and the gynecologic oncologist recommending carboplatin-paclitaxel as primary peritoneal cancer treatment simultaneously require access to the imaging display system, IHC panel summary, and the NGS tissue-of-origin report showing 65% ovarian probability — cannot fail during the 45-minute board window when 10 CUP patients' treatment decisions are pending tumor board consensus; and where molecularly directed therapy toxicity platform availability at a pembrolizumab Day 21 visit for an MSI-H CUP patient — where the oncology nurse documenting a new dry cough, oxygen saturation of 93% on room air, and bilateral infiltrates on chest X-ray needs the irAE recognition platform to trigger the pneumonitis Grade 2 protocol — withhold pembrolizumab, initiate prednisone 1 mg/kg/day, order high-resolution CT chest — cannot fail when Grade 2 pembrolizumab pneumonitis progressing to Grade 4 ARDS in a patient who receives a third dose of pembrolizumab without steroid intervention represents a preventable immunotherapy death. An NGS report routing platform that delays BRAF V600E result delivery past the tumor board agenda cutoff, a CUP tumor board platform unavailable during the weekly session where 10 newly diagnosed patients await multi-specialty synthesis, a pembrolizumab irAE monitoring platform inaccessible when a nurse needs to document and escalate Grade 2 pneumonitis — these are not IT incidents. They are clinical disruptions in the management of a malignancy defined by its diagnostic complexity, where the difference between molecularly directed therapy and empirical chemotherapy depends on NGS results reaching the tumor board on schedule, and where immunotherapy toxicity monitoring platforms failing at the moment of Grade 2 pneumonitis recognition eliminate the narrow window for preventing fatal immune-related lung injury.
Uptime monitoring gives CUP tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to multi-specialty CUP tumor boards, molecular oncology programs, genomic profiling vendor liaisons, clinical trial coordinators, and compliance auditors that platform operational reliability matches the diagnostic urgency, NGS result routing criticality, multi-specialty tumor board coordination demands, and molecularly directed therapy toxicity monitoring requirements of modern CUP management.
Start monitoring your CUP care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #CUP #carcinomaofunknownprimary #unknownprimary #oncology #NGS #comprehensivegenomicprofiling #FoundationMedicine #Tempus #Caris #IHC #tumorboard #pembrolizumab #PARPinhibitor #BRAFinhibitor #larotrectinib #selpercatinib #osimertinib #PETCT #RECIST #HIPAA #cancertech #healthtech #digitalhealth #uptime #sre